GlassScriptPhysician profile
Dennis Michael Martinez
NPI 1366837379
$1,497.84
in general payments reported to CMS, 2019-2025
13 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $197 · 2024: $391 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.66 | 2023-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $294.46 | 2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $266.73 | 2025 | Uptravi, Opsumit, Opsynvi |
| Jazz Pharmaceuticals INC. | $149.90 | 2022 | |
| Pulmonx Corporation | $62.37 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $35.59 | 2025 | |
| Philips North America LLC | $32.48 | 2025 | Vest Therapy Und |
| Grifols USA, LLC | $29.14 | 2025 | Prolastin-C Liquid |
| Inogen, INC. | $19.50 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.46 | 2025 | Glassia |
| United Therapeutics Corporation | $18.27 | 2025 | Tyvaso |
| Electromed, INC. | $17.16 | 2024 | Smartvest |
| Genentech USA, INC. | $14.12 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.